Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

FLUCLOXACILLIN IMPURITY D CRS(15 MG)

FLUCLOXACILLIN IMPURITY D CRS(15 MG)

3919-74-2

DISCOVER
FLUCLOXACILLIN IMPURITY E CRS(15 MG)

FLUCLOXACILLIN IMPURITY E CRS(15 MG)

NA

DISCOVER
FLUCLOXACILLIN MAGNESIUM OCTAHYDRATE CRS (5 MG)

FLUCLOXACILLIN MAGNESIUM OCTAHYDRATE CRS (5 MG)

58486-36-5

DISCOVER
IMIPRAMINE FOR SYSTEM SUITABILITY CRS (10 MG)

IMIPRAMINE FOR SYSTEM SUITABILITY CRS (10 MG)

113-52-0

DISCOVER
NILUTAMIDE IMPURITY B CRS (5 MG)

NILUTAMIDE IMPURITY B CRS (5 MG)

393-11-3

DISCOVER
ORCIPRENALINE FOR SYSTEM SUITABILITY CRS (5 MG)

ORCIPRENALINE FOR SYSTEM SUITABILITY CRS (5 MG)

5874-97-5

DISCOVER
RACECADOTRIL CRS (120 MG)

RACECADOTRIL CRS (120 MG)

81110-73-8

DISCOVER
RACECADOTRIL IMPURITY A CRS (25 MG)

RACECADOTRIL IMPURITY A CRS (25 MG)

507-09-5

DISCOVER
RACECADOTRIL IMPURITY G CRS (15 MG)

RACECADOTRIL IMPURITY G CRS (15 MG)

NA

DISCOVER
TINIDAZOLE IMPURITY A CRS (15MG)

TINIDAZOLE IMPURITY A CRS (15MG)

88054-22-2

DISCOVER
RACECADOTRIL FOR PEAK IDENTIFICATION CRS (5 MG)

RACECADOTRIL FOR PEAK IDENTIFICATION CRS (5 MG)

81110-73-8

DISCOVER
METHYLPHENIDATE IMPURITY MIXTURE CRS (0.04 MG)

METHYLPHENIDATE IMPURITY MIXTURE CRS (0.04 MG)

NA

DISCOVER